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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this review is to systematically review, synthesise and quantify the effects of non-pharmacological and non-surgical
chronic disease management interventions targeting self-management for people with lower-limb PAD.
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B A C K G R O U N D
Description of the condition
Peripheral arterial disease (PAD) is a chronic atherosclerotic car-
diovascular disease impacting on quality of life and leading to ad-
verse outcomes. The principal symptom of PAD is lower-limb
pain or discomfort (known as intermittent claudication), which is
typically brought on by walking and relieved by rest (Sutherland
2009). As PAD progresses, intermittent claudication may increase
in severity and critical limb ischaemia may develop, which results
in constant lower-limb pain at rest, leg ulceration, sepsis, and pos-
sibly gangrene and the need for amputation (Sutherland 2009).
Several studies have indicated that the prevalence of PAD increases
with age. A large study undertaken in San Diego, US identified a
prevalence of 2.5% in people aged 60 years, 8.3% in those aged 60
to 69 years, and 18.8% in the study participants aged 70 years or
older (Criqui 1985).Of 28,980 Scottishmen andwomen screened
using the ankle-brachial index (ABI), 10.9% of participants had
an ABI which categorised them as ‘at risk’ (with an ABI < 0.9
indicating PAD and increased cardiovascular risk) (Price 2008).
Another Scottish study identified that 4.6% of 2720 participants
aged 55 to 74 years had intermittent claudication (lower-limbpain
or discomfort brought on by walking and relieved by rest) and 8%
had significant impairment of blood flow but were asymptomatic
(Fowkes 1991).
Exercise, in particular regular walking, is a fundamental compo-
nent of lower-limb PAD management (Hirsch 2005; Norgren
2007). Its effectiveness is proven by other Cochrane Reviews
(Bendermacher 2006; Watson 2008). The latter showed that with
exercise, including walking, skipping and running, the pain-free
walking distance mean difference was 82.19 metres (95% confi-
dence interval (CI) 71.73 to 92.65) and the maximum walking
distance mean difference was 113.20 metres (95% CI 94.96 to
131.43) (Watson 2008). The benefits of exercise in PAD may be
facilitated by the reversal of several pathological events that are
common in PAD (for example arterial obstruction, endothelial
dysfunction, altered skeletal muscle phenotype and inflammation)
(Hamburg 2011). There are several important benefits of exercise
for people with PAD. These are improved functional ability, car-
diovascular fitness, physical mobility and psychological well being
(Guidon 2010; Hamburg 2011). However, adhering to regular
exercise can be problematic for people with PAD as the onset of
intermittent claudication can act as a deterrent to exercise par-
ticipation. A recent meta-analysis comparing endovascular treat-
ment of intermittent claudication to supervised exercise reports
that outcomes measured by treadmill walking were no different to
the outcomes of endovascular treatment (Ahimastos 2011). The
authors of the study concluded that “mechanisms that promote
greater access to, uptake and sustainability of SVE (supervised ex-
ercise programs) would appear to be an important requirement
to advance management of intermittent claudication given the
favourable results” (Ahimastos 2011). Not only are access and up-
take of such interventions important, but adherence is fundamen-
tal to the success of interventions such as exercise programs.
Smoking is a substantial risk factor for the development (odds ra-
tio 5.09, 95% CI 2.97 to 8.72) (Leng 1995) and progression of
lower-limb PAD and has significant implications for morbidity
and mortality (Hirsch 2005; Norgren 2007). Quitting smoking
is challenging and specialised support improves the success of at-
tempts to quit (Fiore 2008). Like many other chronic diseases,
people with PAD often experience poor health-related quality of
life (Dumville 2004). There is evidence of socioeconomic disparity
in the prevalence (Kroger 2009) and outcomes (Ferguson 2010)
for people with PAD. Stigma and social marginalisation can be
experienced by smokers (Stuber 2008).
Considering the psychological burden (Smolderen 2009), poor
quality of life (Dumville 2004), risk of acute events (Criqui 2008)
leading to increased morbidity and mortality, and management
strategies requiring behavioural change and long-term adherence,
chronic disease management interventions that aim to improve
self-management may improve outcomes for people with PAD.
Performance measures for management of PAD underscore the
importance of risk assessment, patient education (in particular on
the importance of exercise and smoking cessation), self-manage-
ment (especially adherence to exercise and smoking cessation) and
monitoring of disease status (Olin 2010). Based on this guideline,
non-pharmacological, non-surgical disease management interven-
tions for PAD should incorporate risk assessment, patient educa-
tion, self-management strategies and monitoring of disease status.
Description of the intervention
Surgical and pharmacological interventions can provide symptom
relief and reduce the risk of adverse outcomes for people with
lower-limb PAD. However, benefits to quality of life and other
outcomes can also be gained through non-surgical and non-phar-
macological strategies, in particular, smoking cessation and ex-
ercise. However, adhering to exercise programmes and quitting
smoking can be very challenging and interventions which pro-
mote and support the change of health behaviours and adherence
to prescribed treatments may assist people with PAD to improve
their own health. Health professionals typically refer to this con-
cept as self-management. There is currently a lack of consensus on
the definition of self-management (Gardetto 2011) and self-care
is also often used as an interchangeable term. In this review, we
will use the term self-management for consistency. Self-manage-
ment is a core component of disease management interventions
(Lovell 2011), which are organised programmes or services often
led by a nurse or allied health professional. They aim to increase
self-efficacy (a person’s belief that they can achieve a given task)
and knowledge about the disease, treatment and outcomes (health
literacy) so that the person is better informed and capable of en-
gaging in activities which protect or promote their own health
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(for example exercise participation and quitting smoking), man-
age their symptoms (for example managing intermittent claudi-
cation through medications and pain management strategies), the
impact which lower-limb PAD has on their life, and also adhere
to any prescribed therapies (such as a prescribed exercise regime or
risk-reducing medications). These interventions may be delivered
face-to-face (in a group or one-on-one session), via telephone or
other information communication technologies, such as Internet,
short message service (SMS) or e-mail, and will often involve a
combination of delivery modes. Increasingly the role of disease
management is emphasised to address the burden of chronic con-
ditions, and self-management is a core component of disease man-
agement. Lorig 1993 defines self-management approaches as help-
ing individuals “to make informed choices, to adapt new perspec-
tives and generic skills that can be applied to new problems as they
arise, to practise new health behaviours, and to maintain or regain
emotional stability”. Gardetto 2011 has combined definitions of
self-management by Lorig 2003 and Barlow 2002, defining self-
management as “the individual’s ability (problem solving, decision
making, resource utilization, formation of patient-provider part-
nerships, action planning, and tailoring of daily activities) to un-
dertake and manage day-to-day tasks, inherent lifestyle changes,
physical symptoms, and psychosocial consequences of health and
well-being over the lifetime of an illness”. These definitions em-
phasise the importance of a patient-provider partnership where
information is tailored and targeted to the needs of an individual
and action planning and self-monitoring are integral to achieving
optimal health outcomes. Like in many other chronic conditions,
the role of disease management interventions in PAD is to reduce
symptoms and improve clinical outcomes (Lovell 2011).
How the intervention might work
For many chronic conditions, adhering to both pharmacological
and non-pharmacological interventions is important to improve
survival, functional status and health-related quality of life. Ad-
herence with these recommendations also improves organisational
outcomes such as decreasing admissions to hospital. Promoting
and enhancing self-management strategies is an integral element
of chronic disease management programs which have a strong ev-
idence base across many conditions, such as heart failure (Inglis
2010), chronic obstructive respiratory disease (Effing 2007), os-
teoarthritis and diabetes (Deakin 2005). These approaches recog-
nise the need to shift the focus on purely acute events to a focus on
supporting the individual living with a chronic condition. Incor-
porating critical elements such as patient empowerment, increas-
ing adherence to evidence-based recommendations andpromoting
care coordination can improve health outcomes (Tsai 2005). In-
creasingly, health providers recognise that information alone is not
sufficient to promote adherence and drive behaviour change. This
has led to multiple interventions to assist individuals in adopting
favourable health behaviours and to engage in self-management
strategies. Systematic reviews of integrated disease management
strategies have shown that coordinated strategies and promoting
self-management can improve health outcomes, yet identifying
the key components of interventions is less clear (Coster 2009).
Chronic disease management interventions which are designed to
improve self-management typically focus on increasing self-effi-
cacy, health literacy, symptom monitoring and management, and
adherence. By addressing these important aspects ofmanaging and
living with a chronic disease, these interventions can also improve
outcomes and health-related quality of life. Adherence to exercise
regimes, smoking cessation and risk reducing pharmacotherapies
is important for managing PAD. Making a change to health be-
haviours can be very challenging, especially if this involves a life-
time habit such as smoking or exercise which causes pain and dis-
comfort. These interventions might work by engaging people with
PAD in decisions regarding their own health as well as by using
behavioural change strategies to promote smoking cessation, ex-
ercise participation and other lifestyle modifications.
Why it is important to do this review
Evidence supports the use of chronic disease management inter-
ventions to improve self-management in chronic diseases other
than PAD (Deakin 2005; Effing 2007; Inglis 2010), however it
is unclear what benefits these interventions offer for people with
PAD. To our knowledge, there are no other systematic reviews
of the evidence for chronic disease management interventions to
improve self-management for lower-limb PAD.
O B J E C T I V E S
The objective of this review is to systematically review, synthesise
and quantify the effects of non-pharmacological and non-surgical
chronic disease management interventions targeting self-manage-
ment for people with lower-limb PAD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) of chronic
diseasemanagement interventions to support self-management for
people with lower-limb PAD.
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Types of participants
Adults (aged ≥ 16 years) of either sex, any age or ethnic group
with a diagnosis of lower-limb PAD, ideally defined by the an-
kle-brachial index (ABI) measurement (ABI < 0.9) or diagnostic
equivalent. We will include studies which do not report an ABI or
diagnostic equivalent to confirm diagnosis of PAD but state that
participants were patients with PAD or had intermittent claudi-
cation. Study participants may be from hospital or community
cohorts. We will exclude studies dealing with general cardiac or
vascular disorders rather than specifically with PAD unless the in-
tervention is tailored to individual patient needs (that is addresses
the needs specific to people with PAD and involves the key char-
acteristics of self-management) and data are available for partici-
pants with PAD separate from participants with other cardiac or
vascular disorders.
Types of interventions
We will include chronic disease management interventions de-
signed to engage people with lower-limb PAD in activities that
protect and promote their own health (for example smoking cessa-
tion, diet, exercise). These interventions must have a component
that supports people in understanding, monitoring and managing
symptoms of lower-limb PAD and the impact of lower-limb PAD
has on their life (intermittent claudication) as well as maintaining
lifestyle modifications that are recommended to people with PAD
and adherence to prescribed therapies.
Interventions which involve exercise or everyday physical activity,
or both, will be considered for inclusion. However, in addition
to prescribing or facilitating an exercise regime, the intervention
must be multifaceted and include additional components such as
support in understanding,monitoring andmanaging symptoms of
lower-limb PAD and the impact lower-limb PAD has on their life
(intermittent claudication), as well as maintaining lifestylemodifi-
cations that are recommended to people with PAD and adherence
to prescribed therapies. Interventions with no self-management
component will be excluded. These interventions will include an
active component of support or interaction with the patient as op-
posed to the mere provision of recommendations about therapies
to patients. Education interventions should include some form of
assessment of understanding and follow-up.
These interventions could take the form of, but are not lim-
ited to, interactive education, telemonitoring, self-monitoring, a
peer-support group, coaching and motivational interviewing (Lai
2010). Modifiable risk factors such as smoking and adherence to
exercise can be addressed with behaviour change strategies that
consider the individuals’ beliefs, values and motivation to change.
We will not exclude studies based on the personnel delivering the
intervention and our review may include programmes delivered
by lay personnel (Foster 2007).
We will compare these interventions with usual care, defined as no
specialist chronic disease management intervention aimed at im-
proving self-management. For example, usual care could involve
a patient receiving instructions from a clinician to stop smoking
and commence an exercise programme, but the patient is not en-
rolled in a programme which addresses self-management specifi-
cally and there is no ongoing follow-up of the patient to encourage
or support self-management. Interventions will not be performed
as part of a trial of surgical or pharmacological interventions and
at the same time. The only difference between the intervention
and control arms in terms of care received should be the chronic
disease management intervention to support self-management.
Types of outcome measures
We will not exclude studies based on the outcomes reported. We
will examine immediate outcomes (up to six weeks from the com-
mencement of the intervention), intermediate (up to and includ-
ing one year from the commencement of the intervention), and
longer-term outcomes (measured more than one year after the in-
tervention).
Primary outcomes
We will examine the following as our primary outcomes.
• Functional status will be examined in separate meta-analyses
according to the individual measures of distance, such as:
◦ absolute claudication distance;
◦ initial claudication distance;
◦ the six-minute walk test.
• Functional status will also be examined according to the
individual questionnaires, such as:
◦ Summary Lower Extremity Performance Score (Vogt
1994);
◦ Walking Impairment Questionnaire (Regensteiner
1990);
◦ Baltimore Activity Scale (Gardner 2006).
• Health-related quality of life measured using PAD-specific
validated questionnaires, such as the Intermittent Claudication
Questionnaire (Chong 2002), the Claudication Scale (CLAU-S)
(Spengel 1997); or generic health-related quality of life measures
such as the Medical Outcomes Short-Form (SF) 36 (Ware 1992)
and its related instruments or the EuroQoL (EQ-5D) (The
EuroQol Group 1990).
Secondary outcomes
We will examine the following as our secondary outcomes:
• all-cause mortality;
• revascularisation or amputation;
• acute events (stroke or myocardial infarction);
• self-efficacy for exercise (using validated measures such as
Bandura’s Self-Efficacy for Exercise Scale (Bandura 1994));
• modifiable risk factors (smoking, obesity, blood pressure,
lipids);
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• adherence to prescribed therapies (exercise, medications,
diet);
• patient acceptance and satisfaction with the intervention;
• adverse events.
Adverse events are not a commonly reported outcome in non-
pharmacological, non-surgical chronic disease management stud-
ies, however improved adherence to pharmacological interventions
may lead to increases in adverse event rates and hence these will
be examined, if reported.
Search methods for identification of studies
We will not apply date limits to database searches. We will search
all databases from commencement of the database up to the search
date. Language restrictions will not apply to any of the searches.
Electronic searches
The Cochrane Peripheral Vascular Diseases Group Trials Search
Co-ordinator (TSC) will search the Specialised Register and the
Cochrane Central Register of Controlled Trials (CENTRAL),
part of The Cochrane Library (www.the cochranelibrary.com). See
Appendix 1 for details of the search strategy which will be used to
search CENTRAL. The Specialised Register is maintained by the
TSC and is constructed from weekly electronic searches of MED-
LINE, EMBASE, CINAHL, AMED, and through handsearching
relevant journals. The full list of the databases, journals and con-
ference proceedings which have been searched, as well as the search
strategies used, are described in the Specialised Register section of
the Cochrane Peripheral Vascular Diseases Group module in The
Cochrane Library (www.thecochranelibrary.com).
In addition, the authors will search the following databases using
search strategies based on the CENTRAL search strategy.
• PsycINFO.
• Web of Science.
• ProQuest Dissertations & Theses Database.
• ANU Digital Theses Collection.
• Index to Theses.
Searching other resources
We will review bibliographies of retrieved studies to identify other
relevant studies. We will use citation tracking to identify other
publications related to the included studies or other relevant ref-
erences.
In addition, we will search our personal literature collections for
relevant studies.
We will handsearch conference abstracts to identify relevant ab-
stracts of randomised controlled trials of self-management inter-
ventions for people with PAD. Due to resource constraints, we
will handsearch abstracts for the following conferences for the past
five to 10 years if we are able to obtain copies of abstract books or
access to online resources:
• American Heart Association Annual Scientific Sessions;
• Society for Vascular Surgery Annual Meetings;
• Society for Vascular Nursing Annual Conventions;
• European Society for Vascular Surgery Annual Meetings.
Data collection and analysis
Two review authors will review all identified abstracts and results
from database searches for relevance to the review topic. If the
reference appears relevant, we will obtain a full copy of the refer-
ence for detailed review to determine the inclusion in the review
or exclusion of the study.
Selection of studies
Two review authors will independently review the results of each
search according to the exclusion and inclusion criteria. A third
review author will adjudicate in the instance of disagreement be-
tween the first two review authors.
Data extraction and management
Two review authors will extract data from the included studies in a
blinded manner and a third review author will check all extracted
data for accuracy and consistency. We will use a customised elec-
tronic data extraction form to record all extracted data.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias (method-
ological quality). A third review author will adjudicate in the in-
stance of disagreement between the first two review authors. We
will assess the risk of bias in the following domains using the




• incomplete outcome data;
• selective outcome reporting;
• other sources of bias.
We will rate the assessment of risk of bias as ’unclear risk of bias’,
’low risk of bias’ and ’high risk of bias’ according to the Cochrane
Collaboration tool (Higgins 2011) for assessing risk of bias; exam-
ples from the text will be provided to support this classification.
Measures of treatment effect
Wewill analyse outcomeswhich are continuous variables using dif-
ference in means and the 95% confidence intervals (CI) for stud-
ies using the same outcome measurement scale. In the instance of
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studies reporting the same outcome (for example quality of life or
measures of functional status) but using different measurements,
we will use the standardised mean difference and 95% confidence
interval to report these data.
We will report risk ratios (RR) for outcomes which are dichoto-
mous variables (that is all-cause mortality, revascularisation or am-
putation, and acute events).
Unit of analysis issues
If the included trials report outcomes at more than one time point,
we will report the primary outcome data. That is, the main time
point used in the analysis in the primary publication of the study.
Dealing with missing data
We will contact study authors via e-mail in the instance of missing
or unclear data in order to maximise data synthesis. Where possi-
ble, we will perform all analyses using intention-to-treat analysis,
that is, we will analyse all participants and their outcomes in the
groups to which they were allocated regardless of whether they
received the intervention or whether or not they were assessed for
the outcome. In the event of dropouts, we will adjust the denomi-
nator for the number of participants followed up for each outcome
if these data are available.
Assessment of heterogeneity
We will assess statistical heterogeneity for the outcomes meta-
analysed using the I2 statistic, which describes the percentage of
variability in effect estimates due to heterogeneity (Deeks 2011).
Assessment of reporting biases
Funnel plots allow review authors to make a visual assessment
of whether small-study effects may be present in a meta-analysis
(Sterne 2011). Small-study effects, when the intervention effect
is more beneficial in smaller studies, is considered to be possibly
caused by publication bias.Wewill explore this potential for small-
study effects in the primary outcomes of the review further using
funnel plots if at least 10 studies are included in the meta-analysis
of the primary outcomes (Sterne 2011).
Data synthesis
We will quantitatively meta-analyse primary outcomes and some
secondary outcomes (all-cause mortality, revascularisation, ampu-
tation, stroke ormyocardial infarction, smoking status) depending
on the availability of suitable data from high-quality studies. Con-
sidering the likely heterogeneity in participant populations, inter-
vention characteristics, length of follow-up and outcomemeasure-
ment, we will perform a random-effects meta-analysis.
We will tabulate and describe other outcomes such as adherence,
self-efficacy for exercise, modifiable risk factors (obesity, blood
pressure, lipids) and patient acceptance and satisfaction with the
intervention.
We will include the following outcomes in the summary of find-
ings table: functional status, health-related quality of life, all-cause
mortality, revascularisation, amputation and smoking status.
Subgroup analysis and investigation of heterogeneity
If the number of included studies permits, we will perform sub-
group analyses and investigations of heterogeneity for each out-
come meta-analysed by considering each particular type of inter-
vention. For example, some studies may use a face-to-face in a
group or one-on-one format, other studies may include an Inter-
net, e-mail, telephone-based or SMS delivered intervention. We
will also consider the elements of interventions, that is clinician
delivered, theoretically derived, and the intensity of the interven-
tion, if the number of included studies permits. If the number of
studies permits, we will also perform subgroup analyses to exam-
ine the clinical characteristics of the study participants, such as
history of revascularisation.
Sensitivity analysis
We will perform sensitivity analyses if issues with methodological
quality of the included studies are identified. Additionally, we will
perform a sensitivity analysis to assess the influence of publication
type (full peer-reviewed publication versus abstract or thesis) on
reported outcomes. We will perform further sensitivity analyses to
assess the effect of dropouts on outcomes, that is, in the event of
dropouts we will not adjust the denominator for the number of
participants followed up for each outcome and the denominator
will be the total number of participants randomised to each arm
irrespective of whether or not they were followed up for the out-
come. If a sensitivity analysis indicates the results are influenced by
particular methodological or publication factors, we will discuss
the findings of the review within this context.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Arteriosclerosis, this term only
#2 MeSH descriptor Arteriolosclerosis, this term only
#3 MeSH descriptor Arteriosclerosis Obliterans, this term only
#4 MeSH descriptor Atherosclerosis, this term only
#5 MeSH descriptor Arterial Occlusive Diseases, this term only
#6 MeSH descriptor Intermittent Claudication, this term only
#7 MeSH descriptor Ischemia, this term only
#8 MeSH descriptor Peripheral Vascular Diseases explode all trees
#9 (arter* or vascular or vein* or veno* or peripher*) near (occlus* or reocclus* or re-occlus* or steno* or obstuct* or lesio* or block*
or harden* or stiffen*)
#10 (peripheral near3 dis*)
#11 claudic* or IC
#12 (isch* or CLI)
#13 (leg or limb) near4 (obstruct* or occlus* or steno*)
#14 dysvascular*
#15 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 MeSH descriptor Self Care explode all trees
#17 self near3 (care or help or manag* or directed or monitor* or efficacy or admin*)
#18 symptom near3 (care or help or manag* or directed or monitor* or efficacy or admin*)
#19 MeSH descriptor Patient Education as Topic, this term only
#20 (patient near3 (education or promot*))
#21 (patient near3 (information or care or manage*))
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#22 (health near3 (education or promot*))
#23 health near3 information
#24 empower*
#25 MeSH descriptor Adaptation, Psychological explode all trees
#26 psychologic* near3 adjust*
#27 psychologic* near3 adapt*
#28 cope or copes or coping
#29 adapt* near4 behav*
#30 behav* near4 therap*
#31 behav* near4 intervent*
#32 MeSH descriptor Counseling explode all trees
#33 counsel* or feedback
#34 MeSH descriptor Health Education explode all trees
#35 health near3 literacy
#36 health near3 educt*
#37 MeSH descriptor Motivation, this term only
#38 motivat*
#39 MeSH descriptor Cognitive Therapy, this term only





#45 MeSH descriptor Attitude to Health explode all trees
#46 MeSH descriptor Disease Management, this term only
#47 (disease near3 manag*):ti,ab,kw
#48 MeSH descriptor Managed Care Programs, this term only
#49 (manage* near3 care):ti,ab,kw
#50 MeSH descriptor Patient Care Planning explode all trees
#51 (care near3 (patient or nursing or goal)):ti,ab,kw
#52 MeSH descriptor Delivery of Health Care, Integrated explode all trees
#53 (integrated near3 (health or care* or system or delivery)):ti,ab,kw
#54 ((interdisciplin* or multidisciplin*) near3 (care or health or deliver* or system)):ti,ab,kw
#55 MeSH descriptor Patient Care Management, this term only
#56 MeSH descriptor Patient-Centered Care, this term only
#57 MeSH descriptor Reminder Systems, this term only
#58 (reminder near3 system*):ti,ab,kw
#59 (peer near3 support):ti,ab,kw
#60 (coach*):ti,ab,kw
#61 MeSH descriptor Telemedicine, this term only
#62 (telemedicine or telemonitor*):ti,ab,kw
#63 (self near3 (care or monitor*)):ti,ab,kw
#64 (care near3 plan):ti,ab,kw
#65 (#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30
OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45
OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60
OR #61 OR #62 OR #63 OR #64)
#66 (#15 AND #65)
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